Glenmark gets USFDA nod for generic Lung cancer drug

The company’s product is the generic version of Boehringer Ingelheim Pharmaceuticals Inc’s Ofev capsules.

68
USFDA
Picture: Pixabay

Last Updated on June 29, 2021 by The Health Master

Glenmark Pharmaceuticals yesterday said it has received approval from the US health regulator to market Nintedanib capsules, used in the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer, in the American market.

The Mumbai-based drug major has received tentative approval from the US Food and Drug Administration (USFDA) to market the product in the strength of 100 and 150 mg, Glenmark Pharmaceuticals said in a statement.

The company’s product is the generic version of Boehringer Ingelheim Pharmaceuticals Inc’s Ofev capsules.

According to IQVIA sales data for the 12-month period ending April 2021, the Ofev capsules (100 mg and 150 mg) had achieved annual sales of around $1.6 billion.

USFDA okays Tocilizumab for treatment of Covid-19

Zydus Cadila gets tentative nod from USFDA for Pemetrexed for Injection

Cipla gets USFDA nod for Inhalation product

Zydus Cadila gets tentative nod from USFDA for Fingolimod Capsules

Alkem gets two observations from USFDA for USA plant

Lupin gets USFDA nod for treatment of Kidney patient

Latest Notifications: DMROA (Drugs and Magic Remedies Act)

Copyright – An article (Part-1)

FDA takes action against 115 offenders for black marketing of C-19…

DIPSAR to organize FDP for Pharmacy Colleges

Pfizer stops distribution of Anti Smoking Drug

PCI releases draft syllabus for Diploma in Pharmacy

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner